natgillin/translations-raw huggingface dataset:
A device for magnetically transferring indicia to a wet coating composition applied to a substrate, said wet coating composition comprising at least one type of magnetic or magnetizable particles, and said device comprising a body of permanent-magnetic material, the body of permanent-magnetic material being permanently magnetized in a direction substantially perpendicular to a surface of said body of permanent-magnetic material, wherein 
Uređaj za magnetsko prenošenje oznaka, poput uzorka ili slike, na vlažnu smjesu za premazivanje koja je nanesena na podlogu, poput lista papira ili tkanine, navedena smjesa za premazivanje sadrži najmanje jednu vrstu magnetskih čestica ili čestica koje se mogu magnetizirati, navedeni uredaj se sastoji od tijela permanentno magnetskog materijala, navedeni magnetski materijal se permanentno magnetizira u smjeru koji je u znatnoj mjeri okomit na površinu navedenog tijela, naznačen time, da
A method for improving crop yields, which comprises applying an effective amount of the acid amide derivative or a salt thereof as defined in any one of the above (1) to (32). 
Postupak za poboljšanje uroda, naznačen time, da uključuje primjenu učinkovite količine derivata amida kiseline formule (I) ili njegove soli, kako je definiran patentnim zahtjevom 1. Derivat amida kiseline formule (1) ili njegova sol: a
A shaking device (300,400) for harvesting small fruit according to one or more of the preceding claims, wherein said support body comprises a means for transmitting a circular or conical oscillation to said sticks (308, 410). 
Vibrirajući uređaj (600, 700) za branje malog voća prema zahtjevu 1, pri čemu element koji služi kao oslonac uključuje sredstvo za odašiljanje kružnih ili koničnih vibracija do štapova (308, 410).
The aqueous formulation according to any of the foregoing claims for use in the treatment of Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za liječenje dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
The resulting board-like, plane pieces of wood 10 subsequently pass a drying equipment for the surface 64 (e. g. UV, hot air or infrared radiation) and an application equipment 65 for the application of an adhesive 20. 
Dobiveni ravni komadi od drva 10 koji imaju oblik ploče nakon toga prolaze kroz opremu za sušenje 64 radi sušenja površine (na primjer, pomoću UV zračenja, vrućeg zraka ili infra-crvenog zračenja) i kroz opremu za nanošenje 65 radi nanošenja adheziva 20.
Table 1 Clinical parameter assessment of day 21 compared to baseline on treated nails and untreated controls 
Tablica 1 - Procjena kliničkih parametara na 21. dan u odnosu na početak tretmana kod tretiranih noktiju i netretiranih kontrola
The package according to any one of claims 16-34, further comprising (d) a composition for the treatment of bacterial vaginosis or aerobic vaginitis and for the re-colonization of vaginal enviromnent. 
Pakiranje u skladu s bilo kojim od patentnih zahtjeva 16-34, naznačeno time što dodatno sadrži (d) pripravak za liječenje bakterijske vaginoze ili aerobnog vaginitisa 1 za rekoloniziranje vaginalnog okoliša.
Distributor power line communication system according to any one of the claims 1-5, characterised in that unmetered drops from the power distribution network are also provided with power line communication filters. 
Sustav distribucije komunikacije preko elektroenergetske mreže prema bilo kojem zahtjevu 1-5, naznačen time što su uz filtere komunikacije preko elektroenergetske mreže također dani nemjereni padovi elektroenergetske mreže.
The process according to claim 1, wherein after said isolation by precipitation, dorzolamide camphorsulfonate is submitted to a further purification through recrystallization to promote enantiomeric enrichment of the (4S,6S) enantiomer achieved and to improve its overall purity profile. 
Postupak prema zahtjevu 1, gdje se nakon navedene izolacije precipitacijom, dorzolamid podvrgne daljnjem pročišćavanju putem prekristalizacije kako bi se poboljšalo enantiomersko obogaćenje dobivenog enantiomera i kako bi se poboljšao njegov ukupni stupanj čistoće.
step 1: formation of a diastereoisomeric tartrate salt of the triazine derivative by reaction of a salt of the triazine derivative with a single enantiomer of tartaric acid, 
korak 1: tvorbu diastereoizomerne tartratne soli derivata triazina reakcijom soli derivata triazina sa jednim enantiomerom vinske kiseline,
A co-suspension according to any preceding claim wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1 -hydroxynaphthalene-2- carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate and benzenesulfonate. 
Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se farmaceutski prihvatljivu sol glikopirolata bira između fluorida, klorida, bromida, jodida, nitrata, sulfata, fosfata, formijata, acetata, trifluoracetata, propionata, butirata, laktata, citrata, tartarata, malata, maleata, sukcinata, benzoata, p-klorbenzoata, difenilacetata ili trifenilacetata, o-hidroksibenzoata, p-hidroksibenzoata, 1-hidroksinaftalen-2-karboksilata, 3-hidroksinaftalen-2-karboksilata, metansulfonata i benzensulfonata.
represents a group represents a hydrogen atom, a fluoro atom or a chloro atom, or a methyl, methoxy, difluoromethyl or trifluoromethyl group; 
R? predstavlja vodikov atom, fluorov atom ili klorov atom, ili skupinu metil, metoksi, difluormetil ili trifluormetil;
A method as claimed in any of Claims 10 to 14, wherein the base is sodium hydroxide. 
Postupak sukladno patentnom jednom od patentnih zahtjeva 11 do 14, naznačeno time, da je osnova hidroksid.
The anti-CD40 antibody or antigen-binding fragment or use of claim 5, wherein said anti-CD40 antibody or antigen-binding fragment thereof comprises an amino acid sequence selected from the group consisting of: 
Monoklonalno antitijelo prema zahtjevu 1, gdje je navedeno antitijelo monoklonalno antitijelo koje sadrži aminokiselinsku sekvencu odabranu iz grupe koja se sastoji od:
Said container can be a cassette or container equipped with a nozzle and may contain single or multiple dose(s). 
Navedena ambalaža može biti kazeta ili pakiranje opremljeno sa štrcaljkom i može sadržavati jediničan ili višedoziran pripravak.
Suitable plasticizers are 1,2-propylene glycol, triethyl citrate, polyethylene glycol, dibutyl sebacate and triacetin, with triethyl citrate being the preferred plasticizer. 
Pogodni plastifikatori su 1,2-propilen-glikol, trietil-citrat, polietilen-glikol, dibutil-sebakat i triacetin, gdje je poželjan plastifikator trietil-citrat.
For example, the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like. 
Kao primjer, farmaceutski pripravak može se, primjerice, formulirati u obliku farmaceutskih pripravaka za oralnu primjenu, poput granula, sitnih granula, prašaka, tvrdih kapsula, mekih kapsula, sirupa, emulzija, suspenzija, otopina 1 slično, ili u obliku farmaceutskih pripravaka za parenteralnu primjenu, poput injekcija za intravensku, intramuskularnu ili supkutanu primjenu, infuzija na kap, transdermalnih pripravaka, transmukoznih pripravaka, kapi za nos, inhalansa, supozitorija 1 slično.
A method for treating a disease mediated by a P2X3 or P2X2/3 receptor antagonist, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (I) according to claim 1. 
Uporaba spoja prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za liječenje bolesti posredovane antagonistom receptora P2X3ili P2X2/3.
Container (1) as claimed in one of the preceding claims, characterized in that the predetermined breaking line (5) of the wall section (4) is substantially formed as a perforation. 
Spremnik (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time da je unaprijed određena linija loma (5) dijela stijenke (4) u osnovi oblikovana kao perforacija.
Adding too high a level of Y2O3, e.g. 
Dodavanjem previsoke razine Y20; npr.
The method of claim 15, comprising conversion of the alcohol group of the cis-alcohol of formula Va to a suitable leaving group LG resulting in the compound of formula VI. 
Postupak prema zahtjevu 15, obuhvaća pretvorbu alkoholne skupine cis-alkohola formule Va u odgovarajuću odlaznu skupinu LG što daje kao rezultat spoj formule VI. iVD
The process of claim 8, wherein the vaccine is a trivalent influenza vaccine. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da cjepivo jest trovalentno cjepivo protiv gripe.
The robotic arm of claim 8 wherein said extension member at least one end of said main beam member includes an oppositely disposed pair of said extension members, and wherein at least one of said at least two electrically insulated support posts is mounted at said distal end of each said extension member. 
Robotska ruka prema zahtjevu 8, naznačena time, da navedeni nosivi nastavak na barem jednom kraju od navedenog glavnog grednog elementa, obuhvaća jedan nasuprotno položeni par (36, 38) navedenih nosivih nastavaka, te je pritom najmanje jedan od navedena najmanje dva električno izolirana potporna stupa, montiran na spomenutom distalnom kraju od svakog od spomenutih nosivih nastavaka.
Process for the preparation of compounds of formula (I) according to claim 1 comprising the reaction of compound of formula (II), wherein Ar is a phenyl group substituited in the 3 (meta) position by a group R1 wherein R1 has the same meaning as defined in claim 1, with an amine of formula NHR, wherein R has the same meaning as defined in claim 1. 
O N- N-N- QD) gdje Ar je fenl skupina supstituirana u položaju 3 (meta) skupinom R, gdje R, ima isto značenje kao što je definirano u zahtjevu 1, sa aminom formule NHR, gdje R ima isto značenje kao što je definirano u zahtjevu 1.
The suspension was hydrogenated under 55psi pressure at room temperature during 3h. 
Suspenziju se 3 sata hidrogenira pod tlakom od 379,2 kPa (55 psi), na sobnoj temperaturi.
After the blanks have been transferred to the final mold, the neck ring arms 14 are moved to their open position (FIG. 3) and the invert base 12 is rotated back to its first position transferring the neck ring arms 14 back to the blank side of the assembly in preparation for a subsequent cycle. 
Nakon što su kalupi prenijeti u završni kalup, hvataljke izdanka kalupa se vraćaju u otvoreni položaj, te je baza okretanja zakrenuta natrag u svoj početno položaj, i tako su hvataljke izdanka kalupa ponovo prenijete na stranu prvog kalupa, kao priprema za sljedeći ciklus.
The two agents are preferably administered within 4 hours of each other. 
Dva agensa se pogodno daju unutar 4 sata jedan od drugog.
The liquefied gas treatment system according to claim 1, further comprising a forcible vaporizer configured to forcibly vaporize the LNG stored in the cargo tank and supply the forcibly vaporized LNG to the compressor. 
Postupak obrade ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se, kada se LNG uskladišten u spremniku za teret dovodi u pomoćni motor, teške ugljikovodike kao komponentu odvaja od LNG-a kako bi se podesilo metanski broj LNG-a do vrijednosti potrebne za pomoćni motor.
Preferably, the linker is linked to the cell binding agent via a function reactive towards thiol, sulfide or disulfide bond. 
Konjugat u skladu s patentnim zahtjevom 3, naznačen time što je navedena povezujuća skupina tiolna, sulfidna ili disulfidna skupina.
The process of embodiment 6, wherein the infectious agent is selected from the group consisting of: human metapneumovirus; mumps virus; Rubellavirus; SARS coronavirus; M-strains of Rhinovirus; SV-40 polyomavirus; BK polyomavirus; JC polyomavirus; swine vesicular disease virus; Teschen-Talfan virus; C.trachomatis; C.pneumoniae; C.psittaci; canine parvovirus; and porcine parvoviruses. 
Postupak prema patentnom zahtjevu 1, naznačen time, da infekcijski agens jest jedan ili više od sljedećih patogena: humani metapneumovirus (HMPV); virus mumpsa; respiratorni sincicijski virus (RSV); humani coronavirusi; SARS corona virus; M sojevi Rhinovirusa; svinjski vezikularni virus (SVDV); pseći Parovirus, Teschen-Talfan virus; C. trachomatis; C. pneumoniae; C. psittaci.
A method as claimed in any of Claims 1 to 5 wherein the binding affinity of the mutant for the selected ligand is substantially the same or greater than the binding affinity of the parent for the selected ligand. 
Metoda iz Zahijeva 1-5 naznačena time da je sklonost vezanju mutacije na odabrani ligand u bitnome jednaka ili veća od sklonosti vezanju izvora na odabrani ligand.
the second fusion protein is SEQ ID NO:3 or an amino acid that is at least 95% identical to SEQ ID NO:3. 
(b) drugi fuzijski protein je SEQ ID NO:3 ili aminokiselina koja je najmanje 95% identična sa SEQ ID NO:3.
prepared for administration to the subject prior to the subject experiencing muscle damage or disease; or prepared for administration from about 0.01 µg/kg and about 1000 mg/kg of the subject's weight, such as about 0.1 mg/kg and about 1000 mg/kg of the subject's weight or about 0.2 mg/kg and about 2 mg/kg of the subject's weight; or 
Laminin-1 za primjenu prema zahtjevu 1, naznačenu time da je taj laminin-1 pripremljen za primjenu u količini od 0.01 ug/kg do 1000 mg/kg tjelesne težine dotične osobe, po mogućnosti u količini od 0.1 mg/kg do 1000 mg/kg tjelesne težine dotične osobe ili u količini od 0.2 mg/kg do 2 mg/kg tjelesne težine dotične osobe.
Another aspect of the present invention pertains to uses of the compounds of Formula (I), as described herein, for the manufacture of a medicament for use in the treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes. 
Slijedeći aspekt prikazanog izuma odnosi se na uporabu spojeva Formule (IT), kako je već ovdje opisana, za izradu lijeka za uporabu u liječenju metabolički pripadajućeg poremećaja izabranog iz skupine koju čine dislipidemija, ateroskleroza, koronarno srčano oboljenje, inzulinska rezistencija, debljina, smanjena tolerancija glukoze, ateromatozna oboljenja, hipertenzija, udar, Syndom-X, srčano oboljenje i dijabetes tipa 2.
combining the compound of formula IV with the compound of formula V with a base in a polar solvent; and 
kombiniranje spoja s formulom IV sa spojem s formulom V s bazom u polarnom otapalu; i
In terms of binding to NK1 receptors, the netupitant preferably binds to at least 80 or even 85% of NK1 receptors in the striatum seventy-two hours after administration. 
Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time što navedeni netupitant zauzima najmanje 80% NK, receptora u striatumu sedamdeset i dva sata poslije navedene primjene.
Use of an antisense compound comprising an antisense oligonucleotide complementary to intron 7 of a pre-mRNA encoding human SMN2 in the manufacture of a medicament for use in treating a human subject having spinal muscular atrophy (SMA), wherein the medicament is administered into the cerebrospinal fluid in the intrathecal space of the human subject, wherein the antisense oligonucleotide has a nucleobase sequence consisting of the nucleobase sequence of SEQ ID NO: 1, wherein each nucleoside of the antisense oligonucleotide comprises a modified sugar moiety, wherein each modified sugar moiety is a 2'-methoxyethyl sugar moiety and wherein each internucleoside linkage is a phosphorothioate linkage. 
Uporaba protusmislenog spoja koji sadrži protusmisleni oligonukleotid komplementaran s intronom 7 od pre- MmRNK koja kodira ljudski SMN2 naznačena time što je za proizvodnju lijeka za uporabu za liječenje ljudskog subjekta koji ima spinalnu mišićnu atrofiju (SMA), pri čemu se lijek primjenjuje u cerebrospinalnu tekućinu u intratekalnom prostoru ljudskog subjekta, pri čemu protusmisleni oligonukleotid ima nukleobaznu sekvencu koja se sastoji od nukleobazne sekvence iz SEQ ID NO: 1, pri čemu svaki nukleozid protusmislenog oligonukleotida sadrži modificiranu šećernu skupinu, pri čemu je svaka modificirana šećerna skupina 2'-metoksietil šećerna skupina i pri čemu je svaka internukleozidna veza fosforotioatna veza.
a composition comprising a compound of formula IA or formula IBor a pharmaceutically acceptable salt thereof; a phosphodiesterase-1 (PDE1) inhibitor, a phosphodiesterase-2 (PDE2) inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, or a non-specific PDE inhibitor that inhibits PDE1, PDE2, PDE5, or a combination thereof; and 
Spoj, naznačen time da sadrži: spoj temeljem zahtjeva 1 ili 2, ili kemijski sastav temeljem zahtjeva 3; inhibitor fosfodiesteraze-1 (PDE1), inhibitor fosfodiesteraze-2 (PDE2), inhibitor fosfodiesteraze-5 (PDES), ili nespecifični PDE inhibitor koji inhibira PDE1, PDE2, PDES, ili njihovu kombinaciju; i opcionalno ekscipijens.
a handle with a first trigger assembly and a second trigger assembly, said trigger assemblies being coupled to an articulated applicator arm which is disposed through a drive shaft connected to said handle, said first trigger assembly operative to apply a rotary tack from a distal end of said applicator arm and said second trigger assembly operative to bend said distal end of said applicator arm, wherein a longitudinal axis of said handle is tilted with respect to said drive shaft. 
dršku s prvim sklopom okidača i drugim sklopom okidača, spomenuti sklopovi okidača pričvršćeni na artikuliranu dršku za nanošenje, koja je postavljena kroz pogonsku osovinu koja je spojena na navedenu dršku, pri čemu je navedeni prvi sklop okidača operativan za primjenu rotacijskog ljepljenja s distalnog kraja navedene drške za nanošenje i navedenog drugog sklopa okidača koji djeluje da savije spomenuti distalni kraja navedene drške za nanošenje, pri čemu je uzdužna os navedene drške nagnuta s obzirom na navedenu pogonsku osovinu.
The peptide, the nucleic acid or an expression vector, the cell, or the activated cytotoxic T lymphocyte for use according to claim 13, wherein said medicament is a vaccine. 
Peptid, nukleinska kiselina ili ekspresijski vektor, stanica, aktivirani citotoksični T-limfocit za uporabu u skladu s patentnim zahtjevom 13, pri čemu je lijek cjepivo. HR P20170718 T1
In yet another embodiment the base unit has an annular space for accommodating the dispensing tube. 
Također, u drugoj izvedbi osnovna jedinica ima prstenastu prazninu za prihvat cijevi za točenje.
The term “alkyne” refers to an unsaturated alkyl group having at least one point of alkyne unsaturation (i.e. 
Izraz "alkin" odnosi se na nezasićenu alkilnu grupu koja ima bar jedno mjesto alkinskog nezasićenja (tj.
The method of claim 3 in which the ibudilast or pharmaceutically acceptable salt thereof is administered orally. The method of claim 3 in which the ibudilast or pharmaceutically acceptable salt thereof is administered in an amount of 30 mg to 240 mg daily. 
Ibudilast, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se postupak sastoji u primjeni ibudilasta, ili njegove farmaceutski prihvatljive soli, u količini od 30 mg do 240 mg dnevno.
a heavy chain variable region (VH) comprising the amino acid sequences set forth in SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having at least 80% of identity with said sequences. A ligand comprising: 
- varijabilnu regiju teškog lanca (VH) koja ima sekvence amino kiseline navedene u SEQ ID No. 8; naznačen time da se navedeni ligand veže na anti-ligand koji se nalazi u sekvenci amino kiseline definiranoj sa SEQ ID No.20 ili SEQ ID No. 32, pri čemu je navedeni ligand odabran iz skupine koja se sastoji od protutijela, scFv fragmenta i Fab fragmenta.
A is selected from the group consisting of R3 is hydrogen or methyl; 
A se bira iz skupine koju čine [image] je vodik ili metil;
Examples of these compositions prepared according to the present invention include: cream, ointment, gel, lotion or foam for either skin (including, but not limited to, external genitals, scalp, intertriginous areas) or vaginal application; moreover tablets, pessaries, capsules for vaginal application; possible forms for delayed melting, intended to prolonged release of the active principle; collutorium for mouthwashes, etc. 
HR P20090022 T3 Primjeri ovih pripravaka prema ovom izumu uključuju: kreme, pomade, gelove, losione ili pjene bilo za kožnu (uključujući, ali ne ograničavajući na vanjske genitalije) ili vaginalnu primjenu; štoviše tablete, vaginalete, kapsule za vaginalnu primjenu; moguće oblike za odgođeno topljenje, kojima je namjena produženo otpuštanje aktivne sastojine, itd.
A pallet as claimed in one or more of the claims 2-7, characterised in that in those zones in which the profile is bent at 90°, the pieces of profile (2) which form said first, second and third component (4, 6, 8, 60, 62, 64) comprise first apertures (38) provided to facilitate bending. 
Paleta u skladu s jednim ili više patentnih zahtjeva 2-7, naznačena time što u zonama u kojima je profil svinut pod 90" komadi profila (2) koji čine navedenu prvu, drugu 1 treću komponentu (4, 6, 8, 60, 62, 64) imaju prve otvore (38), načinjene da se olakša savijanje.
: 9-12 and 39, or a salt or solvate thereof. 
: 8-16 ili njegova sol ili solvat.
The process of claim 9, wherein the rinsing of the light stream occurs in a counter-flow of the rinse solution stream with respect to the light stream. 
Proces iz bilo kojeg od patentnih zahtjeva 7 do 11, gdje se ispiranje laganog toka događa u kontra-protoku mlaza otopine za ispiranje u odnosu na lagani tok.
This allows replacement of testosterone by an exogenous androgen, which is safer than endogenous testosterone. 
To omogućuje zamjenu testosterona egzogenim androgenom, koji je sigurniji nego endogeni testosteron.
A compound of Formula II: wherein: 
Spoj s Formulom II: [image] pri čemu:
Examples of C4-8 cycloalkenyl groups include a 1-cyclobutenyl group, 1-cyclopentenyl group, 3-cyclopentenyl group, 1-cyclohexenyl group, 3-cyclohexenyl group, 3-cycloheptenyl group and 4-cyclooctenyl group. 
C2-8-alkinilnu skupinu, nesupstituiranu C3-8-cikloalkilnu skupinu, nesupstituiranu C4-8-cikloalkenilnu skupinu, nesupstituiranu C6-10-arilnu skupinu, nesupstituiranu heterocikličku skupinu, nesupstituiranu